Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BridgeBio PharmaFRA:2CL -2.72%66 Days Sales Outstanding is 87.23 as of Jun. 2026, which is 66% above its 10-year median of 52.40. GuruFocus rates FRA:2CL with a GF Score™ of 66/100 and a GF Value™ of €136.07 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 840 Biotechnology companies, BridgeBio Pharma ranks worse than 57.74% on this metric.
BridgeBio Pharma (FRA:2CL) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
BridgeBio Pharma Days Sales Outstanding Related Terms
BridgeBio Pharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for BridgeBio Pharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2CL vs JAZZ, ASND, EXEL: Days Sales Outstanding Comparison
For the Biotechnology subindustry, BridgeBio Pharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Days Sales Outstanding falls into.
BridgeBio Pharma Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (FRA:2CL) has a Days Sales Outstanding of 87.23 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on BridgeBio Pharma and its competitors. This is 66% above median its historical median of 52.40. Over the past decade, BridgeBio Pharma's Days Sales Outstanding has ranged from 5.32 to 81.14. According to the industry distribution chart, BridgeBio Pharma ranks #485 out of 840 companies in the Biotechnology industry, placing it in the top 57.7%.
Is BridgeBio Pharma's Days Sales Outstanding too high?
BridgeBio Pharma's current Days Sales Outstanding of 87.23 is 66% above median its 10-year median of 52.40. Over the past 10 years, this metric has ranged from a low of 5.32 to a high of 81.14. The Biotechnology industry median Days Sales Outstanding is 69.01. BridgeBio Pharma's value of 87.23 is 26.4% above this industry median. Based on the distribution chart, BridgeBio Pharma ranks #485 out of 840 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BridgeBio Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Days Sales Outstanding compare to JAZZ and ASND?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #485 out of 840 companies for Days Sales Outstanding. This places BridgeBio Pharma in the lower half of its industry. The industry median Days Sales Outstanding is 69.01. BridgeBio Pharma's value of 87.23 is 26.4% above this benchmark. Historically, BridgeBio Pharma's own Days Sales Outstanding has ranged from 5.32 to 81.14 over the past decade. While the company's 10-year median is 52.40 vs. the industry median of 69.01, BridgeBio Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.01, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BridgeBio Pharma's current Days Sales Outstanding of 87.23 is 26.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on BridgeBio Pharma and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Pharma's current Days Sales Outstanding is 87.23, which is 66% above median its own 10-year median of 52.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €136.07, compared to a current price of €58.00 — trading 57.4% below its estimated fair value. The current Days Sales Outstanding is 87.23, which is 66% above median its 10-year median of 52.40 and 26.4% above the Biotechnology industry median of 69.01. BridgeBio Pharma's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Days Sales Outstanding is 87.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?
Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued.
The current stock price of €58.00 is trading 57.4% below its estimated GF Value™ of €136.07.
GuruFocus considers BridgeBio Pharma to be Possible Value Trap.
Key valuation signals for FRA:2CL:
Days Sales Outstanding: 87.23 (66% above median its 10-year median of 52.40)
GF Value™: €136.07 vs. price of €58.00 (57.4% below fair value)
Industry Position: 26.4% above the Biotechnology median (#485 of 840)
No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
66GF Score
Get the complete analysis for FRA:2CL
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2CL has been successfully added to your 
